Key clinical point: No identifiable safety concerns were found among women who were pregnant while participating in tildrakizumab clinical trials.
Major finding: Pregnancy outcomes among 14 women taking tildrakizumab included 6 fetal losses, 4 elective abortions, and 8 live births, with no congenital anomalies.
Study details: The data come from a post hoc analysis of nine clinical trials including 528 female patients and 14 reported pregnancies.
Disclosures: The studies were supported by Merck Sharp & Dohme, a Merck & Co. subsidiary; analyses were supported by Sun Pharmaceutical Industries. Lead author Dr. Haycraft and other authors disclosed relationships with Sun Pharmaceutical Industries, as well as Celgene, Lilly, Novartis, Ortho-Derm, and Pfizer.
FROM THE BRITISH JOURNAL OF DERMATOLOGY